Senator Ted Cruz, R-Texas, has reintroduced a bill he thinks will speed US approval of drugs, biologics, or devices approved in other countries.
Senator Ted Cruz, R-Texas, reintroduced a bill he thinks will speed US approval of drugs, biologics, or devices approved in other countries.
The bill, called Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act, or the RESULTS Act, would give the Food and Drug Administration (FDA) 30 days after a company sends in an application to decide whether it wants to greenlight a drug, device, or biologic approved in another country.
It’s at least the third time Cruz has introduced the bill (the last 2 times were in 2015 and 2017), which would give Congress the power to override an FDA rejection of a product. The 2 other cosponsors are Senators Ron Johnson, R-Wisconsin, and Mike Lee, R-Utah.
Cruz has said the bill could put downward pressure on the prices of drugs and devices as well as alleviate drug shortages.
The bill orders the FDA to review drug and device applications within 30 days and allow “reciprocal approval” of therapies from the European Union, Israel, Australia, Canada, and Japan.
In previous years, health advocates and FDA observers have noted pitfalls with the idea. For one thing, the idea of giving a political body such as Congress the power to overrule the FDA’s scientific experts on matters relating to public health, safety, efficacy, science, and other concerns raises major concerns.
Cruz, like some other conservatives, say that US patients don’t have speedy access to possible life-saving treatments. In a previous press release about the RESULTS Act, he said it is time for a “supply-side medical revolution.”
Last year, conservatives saw one related victory with the passage of the so-called right-to-try law. The Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 creates an alternative pathway for dying patients who do not qualify for a clinical trial. The law bypasses the FDA's current expanded access and compassionate use programs and allows patients to appeal directly to drug companies.
That law, too, was based on the idea that the FDA does not move quickly enough.
The FDA approved 59 drugs in 2018, compared with 46 in 2017. Other studies have said that the FDA acts on applications more quickly than other regulatory authorities.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.